SignalFDA/Bio

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Phase 3 Aspire results provide pivotal efficacy data for Angelman Syndrome treatment.

What changed

Why it matters

Phase 3 Aspire results provide pivotal efficacy data for Angelman Syndrome treatment.

Sources